Discounted Cash Flow Rating

Neutral

Return on Equity Rating

Sell

Debt to Equity Rating

Sell

Price to Earnings Rating

Strong Buy

Analyst Rating

Neutral

Simple Moving Average

Buy

Exponential Moving Average

Buy

Relative Strength Index

Strong Buy

Standard Deviation

Strong Buy

Williams %R

Strong Buy

Average Directional Index

Sell

Insider Trading

Neutral

Wall Street Data Solutions Rating

Buy

A

Marker Therapeutics, Inc. Common Stock (MRKR)

Pharmaceutical Preparations

http://www.markertherapeutics.com

Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and innovative peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from its MultiTAA T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells expressing those targets. It is also developing peptide-based immunotherapeutic vaccines for the treatment of metastatic solid tumors, as well as PolyStart.

4551 KENNEDY COMMERCE DR.
HOUSTON, TX

Current Price

---.--

% Change Today

0.00%

Change Amt. Today

0.00

Active Status

Active

Listing Date

01/07/1998

Market Cap

30,770,895

Shares Outstanding

8,890,000

Weighted SO

8,889,020

Total Employees

N/A

Upcoming Earnings

08/12/2024

Similar Tickers

LUMO --.--%

XCUR --.--%

PTIX --.--%

PMVP --.--%

ANEB --.--%

MIRO --.--%

ZIVO --.--%

BNOX --.--%

AGEN --.--%

Beta

1.5400

Last Div

0.0000

Range

2.4-6.96

Chg

0.2700

Avg Vol

25822

Mkt Cap

30770895

Exch

NASDAQ

Country

US

Phone

713 400 6400

DCF Diff

N/A

DCF

1.1942

Div Yield

0.0000

P/S

8.2552

EV Multiple

-2.0892

P/FV

3.1710

Div Yield %

0.0000

P/E

-2.9850

PEG

-0.0648

Payout

0.0000

Current Ratio

5.9197

Quick Ratio

5.9197

Cash Ratio

3.9551

DSO

243.8416

DIO

0.0000

Op Cycle

243.8416

DPO

54.5686

CCC

189.2730

Gross Margin

-0.9416

Op Margin

-2.9497

Pretax Margin

-2.7643

Net Margin

-2.7653

Eff Tax Rate

0.3147

ROA

-0.8829

ROE

-0.7891

ROCE

-1.1332

NI/EBT

1.0004

EBT/EBIT

0.9372

EBIT/Rev

-2.9497

Debt Ratio

0.0000

D/E

0.0000

LT Debt/Cap

0.0000

Total Debt/Cap

0.0000

Int Coverage

-130.8919

CF/Debt

0.0000

Equity Multi

1.2033

Rec Turnover

1.4969

Pay Turnover

6.6888

Inv Turnover

0.0000

FA Turnover

0.0000

Asset Turnover

0.3193

OCF/Share

-1.2222

FCF/Share

-1.2222

Cash/Share

0.8747

OCF/Sales

-2.9242

FCF/OCF

1.0000

CF Coverage

0.0000

ST Coverage

0.0000

CapEx Coverage

0.0000

Div&CapEx Cov

0.0000

P/BV

3.1710

P/B

3.1710

P/S

8.2552

P/E

-2.9850

P/FCF

-2.8231

P/OCF

-2.8228

P/CF

-2.8228

PEG

-0.0648

P/S

8.2552

EV Multiple

-2.0892

P/FV

3.1710

DPS

0.0000

Latest Headlines (EST)

GlobeNewswire Inc. Jan 22, 07:30 Marker Therapeutics Receives Approval from United States Adopted Name (USAN) Council and International Nonproprietary Names (INN) Expert Committee for “Neldaleucel” as Nonproprietary Name for MT-601 GlobeNewswire Inc. Dec 21, 11:00 Marker Therapeutics Announces Participation in Biotech Showcase and the 19th Annual Non-Dilutive Funding Summit During “J.P. Morgan Week 2024” GlobeNewswire Inc. Nov 09, 17:00 Marker Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Updates

Revenue Product Segmentation